DaVita Clinical Research Announces Scientific Collaboration with Dr. Jon Ruckle
December 19 2013 - 7:00AM
Business Wire
DaVita Clinical Research® (DCR®), a specialty contract research
organization with services spanning the full spectrum of drug and
device development, announced today a non-exclusive agreement with
Pacific Pharma Group, LLC, to provide consulting, program strategy
and protocol design support for clinical pharmacology studies
performed at DCR.
Jon Ruckle, M.D., CPI, principal at Pacific Pharma Group, will
collaborate with DCR to continue to expand DCR’s Phase I research
capabilities. Dr. Ruckle has served as investigator for more than
350 studies across multiple therapeutic areas including diabetes,
cardiovascular disease, hypertension and osteoporosis, as well as
first-in-human trials with biologics and small molecules.
“We are excited to enter into this consulting relationship with
Pacific Pharma Group and to extend our scientific team to
include the experience of Dr. Ruckle,” said Chad Jaeger, vice
president of early clinical research at DCR. “Our intense focus on
patient safety and scientific integrity in complex clinical
pharmacology services aligns well with this collaboration and the
needs of our customers.”
In addition to serving as principal at Pacific Pharma Group, Dr.
Ruckle is currently assistant clinical professor at the John A.
Burns School of Medicine at the University of Hawaii in Honolulu.
Previously, he held medical director positions at Comprehensive
Clinical Development, Inc., Covance Clinical Research Unit and
Radiant Research Unit Honolulu. He was medical director and
co-founder of Northwest Kinetics, Inc., and has authored more than
30 medical publications.
“State-of-the-art, hospital-based Phase I facilities offering
access to both patient and healthy normal populations are of great
interest to pharmaceutical researchers,” said Dr. Ruckle. “Through
our relationship with DCR, Pacific Pharma Group will be able to
offer clients access to these valuable services.”
Dr. Ruckle completed his medical degree at the Loma Linda
University Medical School in Loma Linda, Calif., and his internal
medicine residency training at the Mayo Clinic in Rochester, Minn.
Dr. Ruckle is board certified in Internal Medicine and is a
Certified Physician Investigator through the Academy of
Pharmaceutical Physicians and Investigators.
To learn more about DCR and upcoming clinical research trials,
visit participateDaVita.com or DCR on Facebook.
DaVita® (NYSE: DVA) and DaVita HealthCare PartnersSM are
trademarks or registered trademarks of DaVita HealthCare Partners
Inc. All other trademarks are the property of their respective
owners.
About DaVita
DaVita is the dialysis division of DaVita HealthCare Partners
Inc., a Fortune 500® company that, through its operating divisions,
provides a variety of health care services to patient populations
throughout the United States and abroad. A leading provider of
kidney care in the United States, DaVita delivers dialysis services
to patients with chronic kidney failure and end stage renal
disease. DaVita strives to improve patients’ quality of life by
innovating clinical care, and by offering integrated treatment
plans, personalized care teams and convenient health-management
services. As of Sept. 30, 2013, DaVita operated or provided
administrative services at 2,042 outpatient dialysis centers
located in the United States serving approximately 166,000
patients. The company also operated 66 outpatient dialysis centers
located in 10 countries outside the United States. DaVita supports
numerous programs dedicated to creating positive, sustainable
change in communities around the world. The company’s leadership
development initiatives and social responsibility efforts have been
recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu.
For more information, please visit DaVita.com.
About DaVita Clinical Research (DCR)
DaVita Clinical Research (DCR), a wholly owned subsidiary
of DaVita HealthCare Partners Inc., uses its extensive,
applied database and real-world healthcare experience to assist
pharmaceutical and medical device companies in the design,
recruitment and completion of retrospective, prospective
pragmatic and clinical trials. DCR’s scientific and
clinical expertise spans the lifecycle of product development with
more than 150 client companies.
DCR’s Biorepository, Early Clinical Research unit
(Phase I-IIa) and Clinical Development (Phase IIb through
post-marketing) network of physicians and investigative sites,
data research, Health Economics & Outcomes
Research, Central Laboratory, and Medical
Communications are focused on providing world-class research
in both complex/specialty populations and therapeutic areas, and
especially in CKD and ESRD populations. To learn more about DCR,
visit www.davitaclinicalresearch.com.
DaVitaBianca Violante,
303-876-6614bianca.violante@davita.com
DaVita (NYSE:DVA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Jul 2023 to Jul 2024